TD Asset Management
ATRA icon

TD Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

TD Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,472
Closed -$303K – 1368
2024
Q1 		$303K Buy
+17,472
New +$310K ﹤0.01% 1338
2019
Q3 		– Sell
-541
Closed -$272K – 1336
2019
Q2 		$272K Sell
541
-1,479
-73% -$1.04M ﹤0.01% 1261
2019
Q1 		$2.01M Buy
2,020
+148
+8% +$138K ﹤0.01% 907
2018
Q4 		$1.63M Buy
1,872
+52
+3% +$48.3K ﹤0.01% 961
2018
Q3 		$1.88M Buy
1,820
+96
+6% +$93.9K ﹤0.01% 1009
2018
Q2 		$1.58M Buy
1,724
+80
+5% +$85.9K ﹤0.01% 1014
2018
Q1 		$1.6M Buy
+1,644
New +$1.5M ﹤0.01% 940

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $2.15B AUM 20% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return